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1. Introduction 
Simultaneously with the rapid development of a wide range of antibacterial agents since the 
1940s, bacteria have proved extremely adept at developing resistance to each new employed 
agent. The rapidly increasing incidence of bacterial resistance to antimicrobial agents has 
become a serious problem worldwide. Resistance mechanisms have been identified and 
described for all known antibiotics currently available for clinical use (Fluit et al., 2000).  
The synthesis and evaluation of the biological activity of the new metal-based compounds is 
the field of growing interest. Numerous complexes based on palladium(II) and platina(IV)-
ion have been synthesized and their different biological activities have been documented 
(Agarwal, 2007; Mishra et al., 2007a; Mishra & Kaushik, 2007). The impact of different 
palladium and platinum complexes on the growth and metabolism of various groups of 
microorganisms has been studied. Garoufis et al. (2009) reviewed numerous scientific 
papers on anti-viral, antibacterial and antifungal activity of palladium(II) complexes with 
different types of ligands (sulfur and nitrogen donor ligands, Schiff base ligands and drugs 
as ligands). There are other papers in the literature showing different intensity of 
palladium(II) and platina(IV) complexes activity on various species of bacteria and fungi 
(Kovala-Demertzi et al., 2001; Brudzinska et al., 2004; Coombs et al., 2005; Guerra et al., 2005; 
Ali et al., 2006; Manav et al., 2006; Aghatabay et al., 2007; Kizilcikli et al., 2007; Mishra et al., 
2007b; Biyala et al., 2008; Al-Hazmi et al., 2008; Vieira et al., 2009). 
The aim of this paper is to describe synthesis of some new palladium(II) and platinum(IV) 
complexes and in vitro research of their antibacterial activities. The second objective is to 
evaluate the impact these compounds have on probiotic bacteria. Probiotics are used as 
supplements and they play significant role in protecting and maintaining the balance of 
intestinal microflora in antibiotic therapy. 
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2. Experimental 
2.1 Chemistry 
The palladium(II) and platinum(IV) complexes were obtained by direct reaction of the 
corresponding starting compounds (K2PdCl4 and K2PtCl6) and newly synthesized 
tetradentate or bidentate ligands. The next compounds were synthesized: 
- O,O′-dipropyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate (L1) 
- dichlorido-(O,O′-dipropyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate)-palladium(II) 
(C1) 
- O,O′-dibutyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate (L2) 
- dichlorido-(O,O′-dibutyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate)-palladium(II) 
(C2) 
- O,O′-dipentyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate (L3) 
- dichlorido-(O,O′-dipentyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate)-palladium(II) 
(C3) 
- O,O′-ethyl-(S,S)-ethylenediamine-N,N′-di-2-(3-methyl)-butanoate (L4)  
- chorido((S,S)-ethylenediamine-N-(O-ethyl-2-(3-methyl)-butanoate)-N′-2-(3-methyl)-
butanoato)-palladium(II) (C4)  
- tetrachlorido(O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-methyl)butanoate)-
platinum(IV) (C4a)  
- O,O′-dipropyl-(S,S)-ethylenediamine-N,N′-di-2-(3-methyl)-butanoate (L5)  
- chorido((S,S)-ethylenediamine-N-(O-propyl-2-(3-methyl)-butanoate)-N′-2-(3-methyl)-
butanoato)-palladium(II) (C5) 
- O,O′-dibutyl-(S,S)-ethylenediamine-N,N′-di-2-(3-methyl)-butanoate (L6)  
- chorido((S,S)-ethylenediamine-N-(O-butyl-2-(3-methyl)-butanoate)-N′-2-(3-methyl)-
butanoato)-palladium(II) (C6) 
- O,O′-dipentyl-(S,S)-ethylenediamine-N,N′-di-2-(3-methyl)-butanoate(L7)   
- chorido((S,S)-ethylenediamine-N-(O-pentyl-2-(3-methyl)-butanoate)-N′-2-(3-methyl)-
butanoato)-palladium(II) (C7)  
- O,O′-diethyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate (L8)  
- dichlorido(O,O′-diethyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate)- 
palladium(II) (C8) 
- O,O′-dipropyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate (L9)  
- dichlorido(O,O′-dipropyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate)- 
palladium(II) (C9) 
- O,O′-dibutyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate (L10)  
- dichlorido(O,O′-dibutyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate)- 
palladium(II) (C10) 
- O,O′-dipentyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate(L11) -
dichlorido(O,O′-dipentyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl)-pentanoate)- 
palladium(II) (C11) 
- S-benzyl-thiosalicylic acid (L12)  
- bis-(S-benzyl-thiosalicylate)-palladium(II) (C12) 
- S-methyl-thiosalicylic acid (L13) 
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- bis-(S-methyl-thiosalicylate)-palladium(II) (C13) 
- S-ethyl-thiosalicylic acid (L14) 
- bis-(S-ethyl-2-thiosalicylate)-palladium(II) complex (C14) 
- S-propyl-thiosalicylic acid (L15) 
- bis-(S-propyl-2-thiosalicylate)-palladium(II) (C15) 
- S-buthyl-thiosalicylic acid (L16) 
- bis-(S-butyl-2-thiosalicylate)-palladium(II) (C16) 
- meso-1,2-diphenyl-ethylenediamine-N,N'-di-3-propanoic acid (L17) 
- dichlorido-(meso-1,2-diphenyl-ethylenediamine-N,N'-di-3-propanoate)-palladium(II) 
(L17a) 
- s-cis-dichlorido-(meso-1,2-diphenyl-ethylenediamine-N,N'-di-3-propanoate)-
platinum(IV) (L17b) 
- O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate (L18) 
- tetrachlorido(O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-propanoate)-
platinum(IV)(C18) 
- O,O'-diethyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate (L19) 
- tetrachorido(O,O'-diethyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate)-
platinum(IV) (C19) 
- O,O'-dipropyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate (L20) 
- tetrachorido(O,O'-dipropyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate)-
platinum(IV) (C20) 
- O,O'-dibutyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate (L21) 
- tetrachorido(O,O'-dibutyl-ethylenediamine-N,N'-di-S,S-(2,2'-benzyl)acetate)-
platinum(IV) (C21) 
2.1.1 The synthesis of the ligands - L1, L2, L3 and corresponding palladium(II) 
complexes – C1, C2, C3  
In 50 mL of dry alcohol (1-propanol, 1-butanol or 1-pentanol), saturated with gas HCl, 1.53 g 
(7.5 mmol) of H2-S,S-eddp was added and the mixture was refluxed for 12 h. The mixture 
was filtered and left in the refrigerator over night. The obtained white powder was filtered 
and air-dried.  
Complexes were obtained by mixing K2[PdCl4] (0.200 g, 0.613 mmol) and equimolar amount 
of the dpr-S,S-eddp·2HCl·3H2O (L1) (0.2546 g, 0.613 mmol), dbu-S,S-eddp·2HCl·3H2O (L2) 
(0.2718 g, 0.613 mmol) or dpe-S,S-eddp·2HCl·2H2O (L3) (0.2780 g, 0.613 mmol) esters. 
During 2 h of stirring 10 cm3 of water solution of LiOH (0.0294 g, 1.226 mmol) was added in 
small portions to the reaction mixture. Within this period, pale yellow precipitates of the 
complexes C1-C3 were obtained, filtered off, washed with cold water, ethanol and ether and 
air dried (Vasić et al., 2010) (Fig. 1.).  
2.1.2 The synthesis of the ligands - L4, L5, L6, L7 and corresponding palladium(II) 
complexes – C4, C5, C6, C7 
In 50 mL of dry alcohol (ethanol, 1-propanol, 1-butanol or 1-pentanol), saturated with gas 
HCl, 2.50 g (7.5 mmol) of (H2-(S,S)-eddv) was added and the mixture was refluxed for 12 h. 
The mixture was filtered off and the filtrate was left for a few days in a refrigerator at 4°C. 
The esters were recrystallized from hot alcohol used for each reaction. 
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Fig. 1. The preparation of some alkyl esters of H2-S,S-eddp and corresponding palladium(II) 
complexes 
Complexes were obtained by mixing K2[PdCl4] (0.200 g, 0.613 mmol) and equimolar amount 
of the L4 (0.241 g, 0.613 mmol), L5 (0.256 g, 0.613 mmol), L6 (0.273 g, 0.613 mmol) or L7 
(0.290 g, 0.613 mmol) esters. During 2 h of stirring 10 cm3 of water solution of LiOH  
(0.0294 g, 1.226 mmol) was added in small portions to the reaction mixture. Within this 
period, pale yellow precipitates of the complexes C4-C7 were obtained, filtered off, washed 
with cold water, ethanol and ether and air dried (Fig.2.). The crystal structure of C4 was 
confirmed by X-ray analysis (Radić et al., 2010b; 2011a). 
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Fig. 2. The preparation of some alkyl esters of H2-S,S-eddv and corresponding palladium(II) 
complexes 
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2.1.3 The synthesis of the ligands - L8, L9, L10, L11 and corresponding palladium(II) 
complexes – C8, C9, C10 and C11  
Thionyl choride (4 cm3, 55 mmol) was introduced into a flask containing 50 cm3 of 
corresponding ice cooled alcohol (ethyl, n-propyl, n-butyl or n-pentyl; anhydrous 
conditions) for 1 h. After addition of 2 g (5.54 mmol) [(S,S)-H4eddl]Cl2 the reaction mixture 
was refluxed for 16 h, filtered off and the filtrate was left for a few days in a refrigerator at 
4°C. The esters were recrystallized from the hot alcohol used for each reaction.  
Complexes were obtained by mixing K2[PdCl4] (0.2 g, 0.61 mmol) and equimolar amount of 
the L8·H2O (0.267 g, 0.61 mmol), L9·H2O (0.277 g, 0.61 mmol), L10·H2O (0.301 g, 0.61 mmol) 
or L11·H2O (0.318 g, 0.61 mmol) esters. During 2 h of stirring 10 cm3 of water solution of 
LiOH (0.0293 g, 1.22 mmol) was added in small portions to the reaction mixture. Within this 
period, pale yellow precipitates of the complexes C8-C11 were obtained, filtered off, washed 
with cold water, ethanol and ether and air dried (Vujić et al., 2010) (Fig.3.). The crystal 
structure of C11 was confirmed by X-ray analysis (Vujić, et al., 2011). 
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Fig. 3. The preparation of some alkyl esters of H2-S,S-eddl and corresponding palladium(II) 
complexes 
2.1.4 The synthesis of the ligands - L12, L13, L14, L15, L16 and corresponding 
palladium(II) complexes – C12, C13, C14, C15, C16  
The thioacid ligands (L12)-(L16) were prepared by alkylation of thiosalicylic acid by means 
of corresponding alkyl halogenides in alkaline water-ethanol solution.  
Thiosalicylic acid (1 mmol) was added to a 100 cm3 round bottom flask containing 50 cm3 of 
30% solution of ethanol in water and stirred. A solution of NaOH (2 mmol in 5 cm3 of water) 
was added to acid suspension. The solution became clear. The corresponding alkyl 
halogenide (2 mmol) was dissolved in 5 cm3 of ethanol and transferred to the stirred 
solution. The resulting mixture was kept overnight at 60°C. The reaction mixture was 
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transferred into a beaker and ethanol was evaporated off on a water bath. Diluted 
hydrochloric acid (2 mol/dm3) was added to the resulting water solution and S-alkyl 
thiosalicylic acid was precipitated as a white powder. The liberated acid was filtered off and 
washed with plenty of distilled water. The product was dried under vacuum overnight. 
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Fig. 4. The preparation of alkyl eters of 2-thiosalicylic acid and corresponding palladium(II) 
complexes 
K2[PdCl4] (0.100 g, 0.3065 mmol) was dissolved in 10 cm3 of water on a steam bath and  
(S-benzyl)-2-thiosalicylic acid (0.1497 g, 0.613 mmol), (S-methyl)-2-thiosalicylic acid (0.103 g, 
0.613 mmol), (S-ethyl)-2-thiosalicylic acid (0.1117 g, 0.613 mmol), (S-propyl)-2-thiosalicylic 
acid (0.1203 g, 0.613 mmol) or (S-butyl)-2-thiosalicylic acid, (0.1289 g, 0.613 mmol) was 
added into the solution. The resulting mixture was stirred for 2h and during this time an 
aqueous solution of LiOH (0.0256 g, 0.613 mmol in 10 cm3 of water) was introduced. The 
complexes (C12- C16) as a yellow precipitate were filtered, washed with water and air-dried 
(Radić et al., 2011) (Fig.4.). The crystal structure of C12 was confirmed by X-ray analysis 
(Dimitrijević et al., 2011). 
2.1.5 The synthesis of the ligand L17 and corresponding palladium(II) complex C17 
and corresponding platinum(IV) complex C17a  
Benzaldehyde (30 g) was refluxed with ammonium acetate (60 g) for 3 hours. The reaction 
mixture was cooled and the product was filtered and washed with ethanol. Recrystallization 
from 1-butanol gave N-benzoyl-N'-benzylidene-meso-1,2-diphenyl-ethylendiamine. 
Hydrolysis of that compound with 70% sulphuric acid under reflux for 1h gave meso-1,2- 
-diphenyl-ethylenediamine as the basic product of hydrolysis. 
3-Chloro-propanoic acid (4.34 g, 0.04 mol) was dissolved in 5 cm3 of water on ice bath and 
carefully neutralized with cold water solution of 5 cm3 NaOH (1.6 g, 0.04 mol). 1,2-
Diphenyl--ethylenediamine (4.24 g, 0.02 mol) was added to this solution. The mixture was 
being stirred for 4 hours at 90°C, and during this period 5 cm3 NaOH water solution (1.6 g, 
0.04 mol) was introduced. After that, 5.6 cm3 6 mol/dm3 HCl was added and resulting 
solution was evaporated to the volume of 7 cm3; 6 cm3 conc. HCl, 6 cm3 of ethanol and 6 cm3 
of ether were added to the mixture. The white precipitate of H2 -1,2-dpheddp·2HCl·1.5H2O 
(L17) was separated by filtration and refined with solution water : ethanol = 1 : 2. The crystal 
structure of L17 was confirmed by X-ray analysis (Radić et al., 2010a). 
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Fig. 5. Reaction pathways in synthesis of meso-1,2-diphenyl-ethylenediamine-N,N'-di-3- 
-propionic acid and corresponding palladium(II) and platinum(IV) complexes. 
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Potassium-hexachloridoplatinate(IV) (0.2 g, 0.411 mmol) was dissolved in 10 cm3 of water 
on a steam bath and 1,2-diphenyl-ethylenediamine-N,N'-di-3-propanoic acid (0.1876 g,  
0.411 mmol) was added. The reaction mixture was heated for 12 hours and during this 
period 10 cm3 of LiOH water solution (0.0394 g, 1.65 mmol) was added in small portions and 
the solution was filtered and evaporated to small volume. The orange precipitate of s-cis-
[PtCl2(1,2-dpheddp)] C17b) was separated by filtration, washed with cold water and air-
dried (Fig. 5). 
2.1.6 The synthesis of the ligands L4, L18 and corresponding platinum(IV) complexes 
C4a, C18 
K2[PtCl6] (0.100 g, 0.205 mmol) and det-(S,S)-eddv (0.080 g, 0.205 mmol) were dissolved in  
25 cm3 of water. The reaction mixture was heated on a steam bath for 3 h during which 
water solution of LiOH·H2O (0.017 g, 0.41 mmol in 10 cm3 of water) was introduced. The 
complex, [PtCl4(det-(S,S)-eddv)] (C4a), as a yellow precipitate was separated by filtration, 
washed with water and air-dried (Fig. 6.).  
In 50 cm3 of dry ethanol, saturated with gas HCl, 1.53 g (7.5 mmol) of H2-S,S-eddp was 
added and the mixture was refluxed for 12 h. The mixture was filtered and left in the 
refrigerator over night. The obtained white powder of O,O'-diethyl-(S,S)- 
-ethylenediamine-N,N'-di-2-propanoate dihydrochloride, det-S,S-eddp·2HCl (L18) was 
filtered and air dried.  
K2[PtCl6] (0.100 g, 0.205 mmol) and det-(S,S)-eddp (0.068 g, 0.205 mmol) were dissolved in 
25 cm3 of water. The reaction mixture was heated on a steam bath for 3 h during which 
water solution of LiOH·H2O (0.017 g, 0.41 mmol in 10 cm3 of water) was introduced. The 
complex, [PtCl4(det-(S,S)-eddp)] (C18), as a yellow precipitate was separated by filtration, 
washed with water and air-dried (Stanković et al., 2011b) (Fig. 7.). The crystal structure of 
C18 was confirmed by X-ray analysis (Stanković et al., 2011b). 
 
NH
H2C
H2C
NH
CH
CH
CHC
HO
O
CHC
HO
O
NH
H2C
H2C
NH
CH
CH
CHC
O
H2C
H3C
O
CHC
O
C
H2
H3C
O
CH3CH2OH
HCl
K2PtCl6
LiOH
NH
H2C
H2C
NH
CH
CH
CHC
O
H2C
H3C
O
CHC
O
C
H2
H3C
O
Pt
Cl
Cl
Cl
Cl
H3C
CH3
H3C
CH3
H3C CH3
H3C
CH3
CH3
H3C
CH3
H3C
(L4) (C4a)  
Fig. 6. Synthesis of the ester det-(S,S)-eddv·2HCl and platinum(IV) complex  
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Fig. 7. Synthesis of the ester det-(S,S)-eddp·2HCl and platinum(IV) complex 
2.1.7 The synthesis of the ligands L19, L20, L21 and corresponding platinum(IV) 
complexes C19, C20, C21  
In 50 cm3 of dry alcohol (ethanol, 1-propanol, 1-butanol) saturated with gaseous HCl, 1.50 g 
(3.65 mmol) of ethylenediamine-N,N'-di-S,S-(2,2ʹ-dibenzyl)acetate acid threehydrate  
(H2-S,S-eddba·3H2O) was added and the mixture was refluxed for 12 h. The mixture was 
filtered and left in the refrigerator over night. The obtained white powder was filtered and 
air-dried.  
K2[PtCl6] (0.100 g, 0.206 mmol) and 0.206 mmol of R2-S,S-eddba·2HCl (0.100 g of de-S,S- 
-eddba·2HCl (L19), 0.106 g of dp-S,S-eddba·2HCl (L20), 0.112 g of db-S,S-eddba·2HCl  
(L21)) were dissolved in 15 cm3 of water. The reaction mixture was heated at 40 °C for 12 h 
and during this period 3.92 cm3 of aqueous 0.105 mol/dm3 LiOH·H2O (0.412 mmol) were 
added in small portions The complexes (C19-C21) as a yellow-orange precipitates were 
collected by filtration, washed with water, corresponding alcohol and ether and air-dried 
(Fig. 8.). The crystal structure of L20 was confirmed by X-ray analysis (Dimitrijević et al., 
2010). 
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Fig. 8. The synthesis of: a) esters (R2-S,S-eddba·2HCl); b) complexes [PtCl4(R2-S,S-eddba)] 
2.2 In vitro antimicrobial assay 
2.2.1 Test substances 
The tested compounds were dissolved in DMSO and then diluted into nutrient liquid medium 
to achieve a concentration of 10%. Antibiotic, doxycycline (Galenika A.D., Belgrade), was 
dissolved in nutrient liquid medium, a Mueller–Hinton broth (Torlak, Beograd). 
2.2.2 Test microorganisms 
Antimicrobial activity of twenty-one palladium(II) and platinum(IV) complexes and their 
ligands was tested against 9 species of bacteria: 6 strains of pathogenic bacteria (including 4 
standard strains: Pseudomonas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212, 
Staphylococcus aureus ATCC 25923; Sarcina lutea ATCC 9341 and 2 clinical isolates: Escherichia 
coli and Salmonella enterica) and 3 species of probiotic bacteria (Bacillus subtilis IP 5832 
PMFKG-P32, Bifidobacterium animalis subsp. lactis PMFKG-P33 and Lactobacillus rhamnosus 
PMFKG-P35 ). All clinical isolates were a generous gift from the Institute of Public Health, 
Kragujevac. The other microorganisms were provided from a collection held by the 
Microbiology Laboratory Faculty of Science, University of Kragujevac. 
2.2.3 Suspension preparation 
Bacterial suspensions were prepared by the direct colony method. The colonies were taken 
directly from the plate and were suspended in 5 mL of sterile 0.85% saline. The turbidity of initial 
suspension was adjusted by comparing with 0.5 McFarland’s standard (0.5 ml 1.17% w/v 
BaCl2×2H2O + 99.5 ml 1% w/v H2SO4) (Andrews, 2005). When adjusted to the turbidity of the 0.5 
McFarland’s standard, bacteria suspension contains about 108 colony forming unites (CFU)/mL. 
Ten-hold dilutions of initial suspension were additionally prepared into sterile 0.85% saline.  
2.2.4 Microdilution method 
Antimicrobial activity was tested by determining the minimum inhibitory concentration 
(MIC) and minimum bactericidal concentration (MBC) by using microdilution plate method 
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with resazurin (Sarker et al., 2007). The 96-well plates were prepared by dispensing 100 µL 
of nutrient broth into each well. A 100 µL from the stock solution of tested compound 
(concentration 2000 µg/mL) was added into the first row of the plate. Then, twofold, serial 
dilutions were performed by using a multichannel pipette. The obtained concentration 
range was from 1000 µg/mL to 7.81 µg/mL. A 10 µL of diluted bacterial suspension was 
added to each well to give a final concentration of 5 x 105 CFU/mL. Finally, 10 µL resazurin 
solution was added to each well inoculated with bacteria. Resazurin is an oxidation–
reduction indicator used for the evaluation of microbial growth. It is a blue non-fluorescent 
dye that becomes pink and fluorescent when reduced to resorufin by oxidoreductases 
within viable cells (Banfi et al., 2003). The inoculated plates were incubated at 37 °C for 24 h. 
MIC was defined as the lowest concentration of the tested substance that prevented 
resazurin color change from blue to pink. Doxycycline was used as a positive control. 
Solvent control test was performed to study an effect of 10% DMSO on the growth of 
microorganism. It was observed that 10% DMSO did not inhibit the growth of 
microorganism. Also, in the experiment, the concentration of DMSO was additionally 
decreased because of the twofold serial dilution assay (the working concentration was 5% 
and lower). Each test included growth control and sterility control. All tests were performed 
in duplicate and MICs were constant. Minimum bactericidal concentration was determined 
by plating 10 µL of samples from wells, where no indicator color change was recorded, on 
nutrient agar medium. At the end of the incubation period the lowest concentration with no 
growth (no colony) was defined as minimum bactericidal concentration. 
3. Results and discussion 
The results of in vitro testing of antibacterial activities of the ligands and corresponding 
palladium(II) and platinum(IV) complex are shown in Table 1-10. For comparison, MIC and 
MBC values of doxycycline are listed in Table 11. The solvent (10% DMSO) did not inhibit 
the growth of the tested microorganisms.  
The intensity of antimicrobial action varied depending on the species of microorganism and 
on the type and concentration of tested compounds. The difference between antimicrobial 
activity of the ligands and corresponding palladium(II) and platinum(IV) complexes is 
noticed and, in general, the most active were palladium(II) complexes.  
The results of antibacterial testing for the ligands (L1, L2, L3) and corresponding 
palladium(II) complexes (C1, C2, C3) are shown in Table 1. The results for 3 strains of 
pathogenic bacteria and 2 species of probiotic bacteria were reported in the paper Vasić et 
al., (2010). Results for S. enterica, Staphyl. aureus ATCC 25923, S. lutea ATCC 9341 and L. 
rhamnosus were first presented in this paper. These ligands and complexes, being compared 
to positive control, showed low to moderate antibacterial activity. MIC and MBC values 
were in range from <7.81 to >1000 µg/mL, depending on the species of bacteria. Gram-
positive bacteria showed higher sensitivity. The most sensitive was S. lutea ATCC 9341, 
where MIC was for C1 and C2 <7.81 µg/mL. The best activity at Gram-negative bacteria 
was shown by C2 to P. aeruginosa ATCC 27853 and E. coli (MIC was 31.25 µg/mL). The 
probiotics showed sensitivity similar to the sensitivity of the other bacteria to the tested 
compounds. Exception is B. animalis subsp. lactis where L2, C2 and L3 inhibited its growth at 
these concentrations: 7.81 µg/mL, 15,63 µg/mL and <7.81 µg/mL. 
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The results of testing the ligands (L4, L5, L6, L7) and their palladium(II) complexes (C4, C5, 
C6, C7) are shown in Table 2 and Table 3. The results of testing for L4 were reported in the 
paper by Stanković et al., (2011a; 2011c). The tested ligands, with few exceptions, show very 
low antimicrobial activity, while palladium(II) complexes show selective and moderate 
activity. Interestingly, L6, L7 and C6, C7 exhibit strong antibacterial activity towards E. coli, 
Staphyl. aureus ATCC 25923 and S. lutea ATCC 9341, MIC ranged <7.81 µg/mL to 31.25µg/mL. 
Probiotic bacteria showed high resistance to the effects of tested substances. The most sensitive 
was B. subtilis IP 5832 to C5 and C4 (MIC was 7.81µg/mL and 15.63 µg/mL).  
The results of testing the ligands (L8, L9, L10, L11) and palladium(II) complexes (C8, C9, 
C10, C11) are shown in Table 4 and Table 5. The ligands and complexes, being compared to 
positive control, with few exceptions, showed low antibacterial activity. MIC and MBC 
values were in range from <7.8 to >1000 µg/mL, depending on the species of bacteria. L9, 
L10 and L11 showed excellent results to S. lutea ATCC 9341 (MIC and MBC <7.81 µg/mL) 
and L10 and L11 to S. lutea ATCC 9341, Staphyl. aureus ATCC 25923 and L. rhamnosus (MIC 
<7.81 µg/mL). In this case the ligands acted better than corresponding complexes and it is 
an exception. The complexes have weak antimicrobial activity and some better influence 
was seen on B. subtilis IP 5832 were MIC was in range from 39.06 to 312.5 µg/mL.  
The results of testing the ligands (L12, L13, L14, L15, L16) and corresponding palladium (II) 
complexes (C12, C13, C14, C15, C16) are shown in Table 6 and Table 7. The results for these 
testing were accepted for publication in the paper by Radić et al., (2011b). All tested 
compounds demonstrated selective and moderate antibacterial activity. Tested ligands, with 
a few exceptions, show very low antimicrobial activity. The activity of corresponding 
complexes was higher than with the ligands. MICs values for ligands were in range from 
250 µg/mL to >1000 µg/mL, and for complexes from 62.5 µg/mL to 1000 µg/mL. The 
Gram-positive bacteria were more sensitive than the Gram-negative bacteria especially by 
the activity of the complexes. The best effect was observed in C16 to S. lutea ATCC 9341 
were MIC and MBC 62.5 µg/mL. MICs for Gram-negative bacteria were at 500 μg/mL and 
1000 μg/mL. The tested complexes (C13) and (C14) exhibited somewhat stronger 
antibacterial activity towards P. aeruginosa ATCC 27853 (MIC = 250 μg/mL). The probiotics 
showed sensitivity similar to the sensitivity of the other bacteria (Radić et al., 2011b).  
 
Species 
L1 C1 L2 C2 L3 C3 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 1 125 >500 62,5 125 31.3 >500 31,25 > 250 250 >500 125 > 500 
Salmonella enterica >1000 >1000 125 125 nt nt 250 500 1000 >1000 250 500 
Pseud. aeruginosa ATCC 27853 1 >500 >500 125 250 >500 >500 31,25 125 250 >500 125 125 
Enter. faecalis ATCC 29212 1 >500 >500 125 250 125 >500 62,5 250 >500 >500 62,5 250 
Staphyl. aureus ATCC 25923 >1000 >1000 62.5 125 nt nt 62.5 125 250 1000 62.5 125 
Sarcina lutea ATCC 9341 1000 1000 <7.8 <7.8 nt nt <7.8 15,6 31,25 125 31,25 31,25 
Lactobacillus rhamnosus nt nt 62.5 500 nt nt 62.5 250 nt nt 62.5 125 
Bifidobact. animalis subsp. lactis 1 125 >500 62,5 125 7.81 >500 15,6 125 <7.81 < 31.25 125 > 500 
Bacillus subtilis IP 5832 1 125 >500 62,5 125 62.5 >500 15,6 125 62.5 >500 62,5 > 500 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL), nt, not tested 
Table 1. Antibacterial activity of the ligands (L1,L2,L3) and corresponding complexes  
(C1, C2, C3). 
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Species 
L4 2 C4 L5 C5 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 500 1000 125 500 125 1000 125 500 
Salmonella enterica 1000 >1000 1000 1000 >1000 >1000 1000 1000 
Pseud. aeruginosa ATCC 27853 1000 1000 500 1000 >1000 >1000 500 1000 
Enter. faecalis ATCC 29212 500 500 500 1000 >1000 >1000 500 >1000 
Staphyl. aureus ATCC 25923 500 500 250 500 250 500 125 500 
Sarcina lutea ATCC 9341 31.25 125 250 250 1000 1000 250 250 
Lactobacillus rhamnosus 1000 1000 500 1000 nt nt 500 1000 
Bifidobact. animalis subsp. lactis 250 500 125 1000 500 >1000 250 >1000 
Bacillus subtilis IP 5832 125 500 15.63 >1000 62.5 >1000 7.81 1000 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL), nt, not tested 
Table 2. Antibacterial activity of the ligands (L4, L5) and corresponding complexes (C4, C5).  
 
Species 
L6 C6 L7 C7 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 15.63 500 31.25 500 15.63 125 <7.81 125 
Salmonella enterica 1000 1000 250 500 1000 1000 1000 1000 
Pseud. aeruginosa ATCC 27853 >1000 >1000 500 1000 500 >1000 500 1000 
Enter. faecalis ATCC 29212 1000 >1000 500 1000 1000 >1000 500 1000 
Staphyl. aureus ATCC 25923 31.25 125 125 125 31.25 125 500 500 
Sarcina lutea ATCC 9341 31.25 31.25 31.25 31.25 <7.81 <7.81 250 250 
Lactobacillus rhamnosus 31.25 250 62.50 125 62.50 250 500 1000 
Bifidobact. animalis subsp. lactis 62.50 1000 62.50 1000 62.50 500 125 >1000 
Bacillus subtilis IP 5832 250 >1000 500 1000 1000 >1000 500 >1000 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL) 
Table 3. Antibacterial activity of the ligands (L6, L7) and corresponding complexes (C6, C7).  
 
Species 
L8 C8 L9 C9 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 625 >1000 625 >1000 312.5 >1000 >1000 >1000 
Salmonella enterica >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
Pseud. aeruginosa ATCC 27853 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
Enter. faecalis ATCC 29212 >1000 >1000 >1000 >1000 >1000 >1000 625 >1000 
Staphyl. aureus ATCC 25923 250 500 500 1000 31.25 125 250 500 
Sarcina lutea ATCC 9341 250 250 500 500 <7.8 <7.8 250 250 
Lactobacillus rhamnosus 1000 1000 500 1000 15.63 125 500 1000 
Bifidobact. animalis subsp. lactis 78 >1000 78 >1000 >1000 >1000 >1000 >1000 
Bacillus subtilis IP 5832 78.13 >1000 39.06 625 625 >1000 78 >1000 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL) 
Table 4. Antibacterial activity of the ligands (L8, L9) and corresponding complexes (C8, C9). 
                                                 
2 Stanković et al., (2011a, 2011c) 
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Species 
L10 C10 L11 C11 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli >1000 >1000 >1000 >1000 625 >1000 312.5 >1000 
Salmonella enterica >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
Pseud. aeruginosa ATCC 27853 >1000 >1000 >1000 >1000 >1000 >1000 312.5 >1000 
Enter. faecalis ATCC 29212 156.3 >1000 625 >1000 >1000 >1000 156.3 >1000 
Staphyl. aureus ATCC 25923 <7.8 125 31.25 125 <7.8 125 500 500 
Sarcina lutea ATCC 9341 <7.8 <7.8 31.25 31.25 <7.8 <7.8 250 250 
Lactobacillus rhamnosus <7.8 <7.8 31.25 62.5 <7.8 <7.8 500 1000 
Bifidobact. animalis subsp. lactis >1000 >1000 >1000 >1000 >1000 >1000 625 >1000 
Bacillus subtilis IP 5832 >1000 >1000 78 >1000 >1000 >1000 312.5 >1000 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL) 
Table 5. Antibacterial activity of the ligands (L10, L11) and corresponding complexes (C10,C11).  
 
Species 
L12 C12 L13 C13 L14 C14 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli >1000 >1000 1000 1000 1000 >1000 500 500 1000 >1000 500 500 
Salmonella enterica 1000 >1000 1000 1000 1000 >1000 500 500 1000 >1000 500 500 
Pseud. aeruginosa ATCC 27853 500 >1000 500 1000 500 >1000 250 500 500 >1000 250 500 
Enter. faecalis ATCC 29212 1000 1000 500 500 1000 1000 500 1000 500 1000 250 500 
Staphyl. aureus ATCC 25923 500 1000 500 1000 1000 1000 500 1000 1000 1000 500 500 
Sarcina lutea ATCC 9341 250 500 250 250 1000 1000 250 250 500 500 250 500 
Lactobacillus rhamnosus >1000 >1000 1000 1000 1000 >1000 500 1000 1000 1000 500 500 
Bifidobact. animalis subsp. lactis 500 500 500 1000 500 500 1000 1000 1000 1000 500 500 
Bacillus subtilis IP 5832 500 500 500 500 500 500 500 500 1000 >1000 250 500 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL) 
Table 6. 3 Antibacterial activity of the ligands (L12, L13, L14) and corresponding complexes 
(C12, C13, C14). 
 
Species 
L15 C15 L16 C16 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 1000 >1000 500 500 >1000 >1000 1000 1000 
Salmonella enterica 1000 >1000 500 1000 >1000 >1000 1000 1000 
Pseud. aeruginosa ATCC 27853 500 >1000 500 1000 500 >1000 500 1000 
Enter. faecalis ATCC 29212 500 1000 250 500 1000 1000 500 1000 
Staphyl. aureus ATCC 25923 500 1000 500 500 >1000 >1000 500 500 
Sarcina lutea ATCC 9341 250 250 500 500 1000 1000 62.5 62.5 
Lactobacillus rhamnosus 1000 >1000 500 >1000 >1000 >1000 1000 1000 
Bifidobact. animalis subsp. lactis 500 1000 250 500 1000 1000 500 1000 
Bacillus subtilis IP 5832 500 500 250 250 1000 >1000 250 500 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum bactericidal concentration (µg/mL) 
Table 7. 4 Antibacterial activity of the ligands (L15, L16) and corresponding complexes (C15,C16).  
                                                 
3 Radić et al., (2011b) 
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The results of in vitro testing of antibacterial activities of the ligand (L17) and corresponding 
palladium(II) (C17a) and platinum(IV) (C17b) complexes are shown in Table 8.  
 
Species 
L17 C17a C17b 
MIC MBC MIC MBC MIC MBC 
Escherichia coli >1000 >1000 250 500 >1000 >1000 
Salmonella enterica >1000 >1000 250 500 >1000 >1000 
Pseud. aeruginosa ATCC 27853 250 >1000 15.63 500 125 500 
Enter. faecalis ATCC 29212 500 >1000 31.25 500 250 500 
Staphyl. aureus ATCC 25923 500 >1000 31.25 500 250 500 
Sarcina lutea ATCC 9341 500 >1000 62.5 500 125 500 
Lactobacillus rhamnosus 125 >1000 62.5 >1000 31.25 >1000 
Bifidobact. animalis subsp. lactis >1000 >1000 31.25 125 250 500 
Bacillus subtilis IP 5832 500 >1000 250 500 250 500 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum microbiocidal concentration (µg/mL) 
Table 8. 5Antibacterial activity of the ligand (L17) and corresponding palladium(II) (C17a) 
and platinum(IV) (C17b) complexes. 
The best activity manifested palladium(II) complex C17a with also the best seen result on  
P. aeruginosa ATCC 27853 (MIC 15.63 µg/mL). The same one at Gram-positive bacteria had 
MIC 31.25 – 62.5 µg/mL. Platinum (IV) complex C17b has weaker activity and the best 
result manifested on L. rhamnosus where MIC was 31.25 µg/mL (Radojević et al., 2011).  
 
Species 
L4 C4a L18 C18 
MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli 500 1000 1000 1000 >1000 >1000 >1000 >1000 
Salmonella enterica 1000 >1000 1000 >1000 >1000 >1000 1000 >1000 
Pseud. aeruginosa ATCC 
27853 
1000 1000 1000 >1000 1000 >1000 1000 >1000 
Enter. faecalis ATCC 29212 500 500 1000 1000 500 1000 1000 1000 
Staphyl. aureus ATCC 25923 500 500 500 1000 500 500 1000 1000 
Sarcina lutea ATCC 9341 31.25 125 31.25 62.5 62.5 125 31.25 62.5 
Lactobacillus rhamnosus 1000 1000 1000 1000 1000 1000 1000 1000 
Bifidobact. animalis subsp. 
lactis 
250 500 500 1000 500 500 1000 >1000 
Bacillus subtilis IP 5832 125 500 500 1000 500 500 500 1000 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum microbiocidal concentration (µg/mL) 
Table 9. 6Antibacterial activity of the ligands (L4, L18) and corresponding complexes (C4a, C18). 
Antibacterial activity of the tested platinum(IV) (C4a, C18) complexes and corresponding 
ligands (L4, L18) are shown in Table 9. Results for these testing was reported in the papers 
Stanković et al., (2011a,c). The ligands and corresponding platinum(IV) complexes 
demonstrated low antimicrobial activity. There was no difference in activities between the 
                                                 
5 Radojević et al., (2011) 
6 Stanković et al., (2011a; 2011c) 
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ligands and corresponding complexes. The ligands and corresponding platinum(IV) 
complexes showed significant antibacterial activity against S. lutea ATTC 9341. MICs values 
were in range from 31.25 μg/mL to 62.5 μg/mL, and MBCs values were from 62.5 μg/mL to 
125 μg/mL. The tested compounds did not affect the growth of Gram-negative bacteria or 
their activities were very low (MIC ranged from 500 μg/mL to >1000 μg/mL, MBC from 
1000 μg/mL to >1000 μg/mL). Also, probiotic bacteria showed high resistance to the effects 
of tested substances. MICs were from 125 μg/mL to 1000 μg/mL, and MBCs were from  
500 μg/mL to >1000 μg/mL (Stanković et al., 2011a,c). 
The results of in vitro testing of antibacterial activities of the ligands (L19, L20, L21) and 
corresponding platinum(IV) (C19, C20, C21) complex are shown in Table 10. 
 
 
Species 
L19 C19 L20 C20 L21 C21 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Escherichia coli >1000 >1000 1000 >1000 >1000 >1000 1000 1000 >1000 >1000 1000 1000 
Salmonella enterica >1000 >1000 >1000 >1000 >1000 >1000 1000 1000 >1000 >1000 1000 1000 
Pseud. aeruginosa ATCC 27853 >1000 >1000 1000 >1000 >1000 >1000 1000 >1000 >1000 >1000 1000 >1000 
Enter. faecalis ATCC 29212 1000 >1000 1000 1000 1000 >1000 250 500 1000 1000 125 500 
Staphyl. aureus ATCC 25923 1000 >1000 500 1000 1000 >1000 250 250 1000 >1000 125 250 
Sarcina lutea ATCC 9341 1000 >1000 7.81 15.625 1000 >1000 15.625 31.25 1000 >1000 31.25 62.5 
Lactobacillus rhamnosus >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
Bifidobact. animalis subsp. lactis 125 250 1000 1000 <31.25 125 500 500 <31.25 250 125 500 
Bacillus subtilis IP 5832 125 250 250 1000 250 250 250 250 250 250 125 250 
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum microbiocidal concentration (µg/mL) 
Table 10. Antibacterial activity of the ligands (L19, L20, L21) and corresponding complexes 
(C19, C20, C21). 
The difference in action between ligands and corresponding complexes can be seen at 
Gram-positive bacteria. Ligands have significant antimicrobial effect on probiotic bacteria 
(L20, L21), and complexes on Gram-positive bacteria (C19, C20, C21). C21 has better 
antimicrobial effect than two other complexes. The lowest antimicrobial action of 
compounds was on Gram-negative bacteria, where tested concentrations of ligands 
almost didn’t have the influence, while corresponding complexes had some better action, 
but still weak and limited. L. rhamnosus also showed similar resistance to the action of 
tested compounds (none of the tested concentrations had the influence on its growth), 
while the other probiotic bacteria were more sensitive, especially to the action of ligands, 
where MIC goes from <31.25 µg/mL to 250 µg/mL. At complexes MIC is in the range 
from125 µg/mL to 1000 µg/mL. 
The gram-positive bacteria were more sensitive than the gram-negative bacteria. The 
platinum(IV) complexes showed high antibacterial activity against Gram-positive bacteria. 
MIC values were in range from 7.81 μg/mL to 1000 μg/mL, and MBC values were from 
15.63 μg/mL to 1000 μg/mL depending on the species of bacteria. The most sensitive was S. 
lutea ATCC 9341 (MIC values are 7.81 μg/mL, 15.625 μg/mL and 31.25 μg/mL for different 
complexes. 
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Species 
Doxycycline 
MIC MBC 
Escherichia coli  7.81 15.625
Salmonella enterica 15.625 31.25 
Pseud. aeruginosa ATCC 27853  62.5 125 
Enter. faecalis ATCC 29212 7.81 62.5 
Staphyl. aureus ATCC 25923 0.224 3.75 
Sarcina lutea ATCC 9341 < 0.448 7.81 
Lactobacillus rhamnosus 7.81 31.25 
Bifidobact. animalis subsp. lactis  31.25 62.5 
Bacillus subtilis IP 5832 1.953 15.625
MIC, minimum inhibitory concentration (µg/mL),  
MBC, minimum microbiocidal concentration (µg/mL) 
Table 11. Antibacterial activity of the positive control - doxycycline  
In general, the ligands demonstrated low and selective antimicrobial activity (with few 
exceptions) and the complexes showed selective and moderate antibacterial activity. MIC 
values were in range from <7.81µg/mL to >1000 µg/mL and MBC values from  
15.625 µg/mL to >1000 µg/mL depending on the species of bacteria. The Gram-positive 
bacteria were more sensitive than the Gram-negative bacteria. The most sensitive species is 
S. lutea ATCC 9341. Tested probiotics, with a few exceptions, indicate high resistance toward 
tested compounds. L. rhamnosus shows the highest resistance among them. The tested 
complexes C1, C2, C3 and C17a exhibit strong activity towards E. coli, P. aeruginosa ATCC 
27853 and E. faecalis ATCC 29212. The L6, L7 and C6, C7 exhibit strong antibacterial activity 
towards E. coli. The tested compounds did not affect S. enterica or their activities were low. 
Some activity showed palladium(II) complexes (C1, C2 , C3, C6 and C17a). At the ligands 
the most effective antimicrobial activity show L6, L7, L9, L10 and L11 while the most active 
complexes are C1, C2, C3, C6 and C17a. For eleven ligands (L1 - L11) and corresponding 
palladium(II) complexes (C1 - C11) antifungal activity is investigated. Palladium(II) 
complexes showed good antifungal activity opposite to ligands. This study are in keeping 
with our research to a great extent (Radojević et al., 2010). 
4. Conclusion 
The intensity of antimicrobial action varied depending on the species of microorganism and 
on the type of tested compounds. The tested ligands, with few exceptions, show low 
antimicrobial activity. The difference between antimicrobial activity of the ligands and 
corresponding palladium(II) and platinum(IV) complexes is noticed and, in general, the 
most active were palladium(II) complexes. The Gram-positive bacteria were more sensitive 
than the Gram-negative bacteria. The most sensitive species is Sarcina lutea ATCC 9341 and 
the most resistant is Salmonella enterica where the tested compounds did not affect or their 
activities were low. Tested probiotics, with a few exceptions, also indicate high resistance 
toward tested compounds.  
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